US · Healthcare · Biotechnology
EPS came in at 0.90 against a street estimate of 0.79 — a beat of 13.9%.
Analysts rate Biomarin Pharmaceutical Inc a buy (23 buy, 6 hold, 0 sell out of 29) with an average price target of $91.42.
CONFIDENT BioMarin posted 20% revenue growth to nearly $1B, raised full-year guidance including VOXZOGO to $1B+, and rapidly integrated Amicus with $220M annual synergies by 2028. Galafold and Pombiliti/Opfolda on track for $1.4B and $1.2B peak sales. Q2 2026 VOXZOGO ~75% revenue from OUS. Galafold in 40 countries; plan 10+ new markets. Pombiliti/Opfolda plan 20+ new markets. Analysts pressed on VOXZOGO competitive durability post-launch and exact switching guardrails (management declined to quantify forward), Amicus synergy waypoints through 2027 (half to slightly >half realized next year), and diagnosis expansion mechanics for Fabry and Pompe (country-by-country EHR, testing, genetic reclassification, family cascade programs). 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 10.24% |
| Dodge & Cox | 7.67% |
| PRIMECAP Management Company | 7.33% |
| Vanguard Capital Management, LLC | 4.46% |
| Vanguard Portfolio Management, LLC | 4.29% |
| NORGES BANK | 4.24% |
| AQR Capital Management LLC | 3.97% |
| State Street Corp | 3.77% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 BIOMARIN PHARMACEUTICAL INC. - DOCUMENT SUMMARY HEADLINE NUMBERS • Company: BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) • Announcement Date: Septemb | 2026-09-15 |
| Board / officer change · Q3 2026 BIOMARIN PHARMACEUTICAL INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Board size increased from 10 to 11 members on September 10, 2026 • Robert Plenge, | 2026-09-14 |
| Company announcement · Q3 2026 BIOMARIN PHARMACEUTICAL INC. - 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • BioMarin Pharmaceutical Inc. completed the acquisition of Alesta Therapeu | 2026-09-01 |
| Material agreement · Q3 2026 BIOMARIN PHARMACEUTICAL INC. - 8-K SUMMARY HEADLINE NUMBERS • BioMarin entered into a binding term sheet with Ascendis Pharma A/S on August 30, 2026 | 2026-08-31 |
| Material agreement · Q3 2026 BIOMARIN PHARMACEUTICAL INC. – 8-K SUMMARY HEADLINE NUMBERS • BioMarin acquiring Alesta Therapeutics B.V. for $275 million upfront cash payment (on | 2026-08-18 |
| Quarterly report · Q2 2026 BIOMARIN PHARMACEUTICAL INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net product revenues Q2 2026: $984.4 million (vs. $813.0 million Q2 2025) – u | 2026-08-06 |
| Results announced · Q3 2026 BIOMARIN PHARMACEUTICAL INC. - Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 total revenues: $990 million, up 20% year-over-year ($165 million | 2026-08-06 |
| Quarterly report · Q1 2026 BIOMARIN PHARMACEUTICAL INC. – Q1 2026 SUMMARY --- HEADLINE NUMBERS • Total Revenues (Q1 2026): $766.2 million (up from $745.1 million in Q1 2025) | 2026-05-05 |
Readable in the app.
| Announcement | Date |
|---|---|
| Entered into Share Purchase Agreement for acquisition transaction BioMarin Pharmaceutical completed its acquisition of Alesta Therapeutics on August 31, 2026. This deal was previously announced on August 18, 2026 via an earlier 8-K filing. BioMarin acquire | 2026-09-01 |
| Entry into term sheet with Ascendis for settlement and license agreement BioMarin Pharmaceutical announced it has entered into a Term Sheet with Ascendis regarding a settlement and license agreement. The company plans to resolve pending legal proceedings between | 2026-08-31 |
| Acquisition of Alesta Therapeutics by BioMarin Pharmaceutical announced BioMarin Pharmaceutical announced it is acquiring Alesta Therapeutics B.V. through a Share Purchase Agreement dated August 17, 2026. The 8-K filing primarily contains standard regulatory dis | 2026-08-18 |
| Completion of merger acquisition of Amicus Therapeutics for $14.50 per share Amicus Therapeutics has been acquired at $14.50 per share in cash. The acquiring company financed this deal by taking on significant debt: a $2.0 billion Term Loan B facility, an $800 millio | 2026-04-27 |
| Merger agreement with Amicus Therapeutics entered into BioMarin Pharmaceutical announced that it has received final regulatory clearance from France's Ministry of Economics and Finance for its merger with Amicus Therapeutics. This was the last m | 2026-04-23 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Biomarin Pharmaceutical Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.